Short-Chain Fatty Acids and Enzymes for FMT-Free C. difficile Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Clostridioides difficile infections, particularly recurrent infections, face challenges such as the lack of a clear mechanism of action, safety concerns with faecal microbiota transplant (FMT), and the risk of negative outcomes for recipients, along with difficulties in determining the impact of gut microbiota changes due to antibiotic exposure and diet variations.
Innovation Solution
The use of specific biochemical compounds like short and medium chain fatty acids (valerate, hexanoate, heptanoate, and bile salt hydrolases) and enzymes to treat C. difficile infections, bypassing the need for FMT by targeting metabolic pathways to inhibit germination and growth, and maintaining a healthy gut microbiota.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If faecal microbiota transplant (FMT) is used to treat recurrent C. difficile infections, then treatment effectiveness is improved, but safety concerns and potential negative outcomes for recipients increase
Solution Approach 1:
The patent extracts and isolates specific beneficial compounds (short-chain fatty acids like valerate, hexanoate, heptanoate, and bile salt hydrolases) from the complex FMT preparation. This allows the therapeutic effects to be achieved without administering the entire microbial ecosystem, thereby eliminating safety concerns associated with FMT while maintaining treatment effectiveness.
Solution Approach 2:
The patent uses purified biochemical compounds as intermediaries to mediate the therapeutic effect. Instead of directly transplanting microbiota, the isolated compounds act as mediators that restore gut microbiota balance and inhibit C. difficile growth, providing a safer alternative that maintains efficacy.
2Reliability
If FMT is used to treat C. difficile infections, then the depleted microorganisms and ecosystem functions in the gut are replaced, but the mechanism of action remains unclear and reproducibility is compromised
Solution Approach 1:
The patent extracts specific active compounds (short-chain fatty acids and bile salt hydrolases) from the complex FMT mixture to identify the actual mechanism of action. This extraction reveals that these specific compounds, rather than the entire microbial community, are responsible for restoring gut microbiota balance and treating C. difficile infections, thereby providing clear mechanistic understanding.
3Reliability
If FMT preparations are administered to treat recurrent CDI, then treatment efficacy is achieved, but concerns regarding composition, stability, and long-term safety increase
Solution Approach 1:
The patent replaces the complex, unstable, and variable FMT preparation with simple, stable, and well-defined purified compounds (short-chain fatty acids and bile salt hydrolases). These purified compounds have known compositions, stable formulations, and predictable shelf lives, eliminating the composition and stability concerns associated with FMT while maintaining treatment efficacy.
4Object-affected harmful factors
If screening methods are developed to evaluate FMT suitability, then safety risks are reduced, but the complexity and difficulty of donor and recipient evaluation increase
Solution Approach 1:
The patent eliminates the need for complex screening methods by extracting and using only the essential therapeutic compounds (short-chain fatty acids and bile salt hydrolases). Since these are purified, well-defined compounds rather than complex microbiota preparations, extensive donor screening and recipient evaluation become unnecessary, thereby reducing safety risks without increasing complexity.
Data Source
AI summary
The invention relates to Clostridioides difficile, and in particular to compounds, polypeptides and mixtures for the treatment of C. difficile infections. The invention also relates to nucleic acids, vectors comprising these nucleic acids and microorganisms for the treatment of C. difficile infections, and to methods of identifying and matching faecal microbiota transplant (FMT) donors to FMT recipients.